PUMA BIOTECHNOLOGY INC (PBYI)

Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Second Quarter Financial Results

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

Puma Biotechnology to Join Russell 3000 Index

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

PBYI Crosses Below Key Moving Average Level

PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024

PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Puma Biotechnology (NASDAQ:PBYI) just reported results for the first quarter of...

Puma Biotechnology Reports First Quarter Financial Results

7 Stocks Under $15 Predicted to Boom in the Next 2 Years

Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Notable earnings after Thursday's close

Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

3 Strong Buy Stocks Under $5: January 2024

A strong buy rating carries weight which speculative investors may want to research in these strong buy stocks under $5.

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference